Evidence map›Paper›PMID 38104096›Full record

ArticleJournal of hematology & oncology2023

Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.

Julie M Vose, Kai Fu, Lu Wang, Adnan Mansoor, Douglas Stewart, Hongxia Cheng, Lynette Smith, Ji Yuan, Hina Naushad Qureishi, Brian K Link and 35 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors.

Julie M Vose *Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA.
Kai Fu *Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Lu Wang *School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Yantai University, Yantai, China.
Adnan MansoorDepartment of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada.
Douglas StewartDepartments of Oncology and Medicine, University of Calgary, Calgary, Canada.
Hongxia ChengDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Lynette SmithDepartment of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA.
Ji YuanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Hina Naushad QureishiDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Brian K LinkDepartment of Internal Medicine, University of Iowa Hospitals & Clinics, Iowa City, Iowa, USA.
Melissa H CessnaDepartment of Pathology, Intermountain Medical Center, Murray, UT, USA.
Paul M BarrDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA.
Brad S KahlDepartment of Medicine, Oncology Division, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Matthew S MckinneyDivision of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Nadia KhanDepartment of Hematology/Oncology, Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Ranjana H AdvaniDivision of Oncology, Stanford Cancer Institute, Stanford, CA, USA.
Peter MartinDivision of Hematology and Oncology, Weill Cornell Medical College, New York, NY, USA.
Andre H GoyJohn Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA.
Tycel J PhillipsDepartment of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI, USA.
Amitkumar MehtaO'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
Manali KamdarDivision of Hematology, University of Colorado, Denver, CO, USA.
Michael CrumpDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre - University Health Network, Toronto, ON, Canada.
Barbara ProDivision of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, USA.
Christopher R FlowersDivision of Cancer Medicine, Department of Lymphoma-Myeloma, MD Anderson Cancer Center, Houston, TX, USA.
Caron A JacobsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Sonali M SmithSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
Deborah M StephensHuntsman Cancer Institute at University of Utah, Salt Lake City, UT, USA.
Veronika BachanovaDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
Zhaohui JinDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Shishou WuDepartment of Pathology, Affiliated Yantai Yuhuangding Hospital, Qingdao University, No.20 Yuhuangding East Road, Yantai, 264000, China.
Francisco Hernandez-IlizaliturriDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Pallawi TorkaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrea Anampa-GuzmánDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Farshid KashefDepartment of Pathology, University at Buffalo, Buffalo, NY, USA.
Xing LiDepartment of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Sunandini SharmaDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Timothy C GreinerDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
James O ArmitageDivision of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA.
Matthew LunningDivision of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA.
Dennis D WeisenburgerDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Robert G BociekDivision of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA.
Javeed IqbalDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA.
Guohua YuDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA. guohuayu@qdu.edu.cn.
Chengfeng BiDivision of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Nebraska Medicine Fred and Pamela Buffett Cancer Center, 505 S 45Th St, Omaha, NE, 68105, USA. andy.bi@unmc.edu.
North American Mantle Cell Lymphoma Consortium

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
NCI NIH HHS P01 CA065493NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundPatients with mantle cell lymphoma (MCL) exhibit a wide variation in clinical presentation and outcome. However, the commonly used prognostic models are outdated and inadequate to address the needs of the current multidisciplinary management of this disease. This study aims to investigate the clinical and pathological features of MCL in the immunochemotherapy era and improve the prognostic models for a more accurate prediction of patient outcomes.

methodsThe North American Mantle Cell Lymphoma Project is a multi-institutional collaboration of 23 institutions across North America to evaluate and refine prognosticators for front-line therapy. A total of 586 MCL cases diagnosed between 2000 and 2012 are included in this study. A comprehensive retrospective analysis was performed on the clinicopathological features, treatment approaches, and outcomes of these cases. The establishment of novel prognostic models was based on in-depth examination of baseline parameters, and subsequent validation in an independent cohort of MCL cases.

resultsIn front-line strategies, the use of hematopoietic stem cell transplantation was the most significant parameter affecting outcomes, for both overall survival (OS, p < 0.0001) and progression-free survival (PFS, p < 0.0001). P53 positive expression was the most significant pathological parameter correlating with inferior outcomes (p < 0.0001 for OS and p = 0.0021 for PFS). Based on the baseline risk factor profile, we developed a set of prognostic models incorporating clinical, laboratory, and pathological parameters that are specifically tailored for various applications. These models, when tested in the validation cohort, exhibited strong predictive power for survival and showed a stratification resembling the training cohort.

conclusionsThe outcome of patients with MCL has markedly improved over the past two decades, and further enhancement is anticipated with the evolution of clinical management. The innovative prognostic models developed in this study would serve as a valuable tool to guide the selection of more suitable treatment strategies for patients with MCL.

Indexed as

Lymphoma, Mantle-CellAdultAntineoplastic Combined Chemotherapy ProtocolsHumansNorth AmericaPrognosisRetrospective StudiesRisk Factors

Identifiers

PMID38104096
PMCPMC10725579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.